BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CND261 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CND261\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07052032-6253@assetmemo.bio
DTSTAMP:20261121T004533Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:CND261: Phase 1 readout est. (NCT07052032)
DESCRIPTION:CND261\, phase 1\, Rheumatoid Arthritis.\nStudy: An Open-label 
 Study of CND261 in Seropositive Rheumatoid Arthritis\nEstimated primary co
 mpletion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cnd261#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07052032
URL:https://assetmemo.bio/drug/cnd261#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
